Cargando…

Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays

CONTEXT: The 250µg-cosyntropin stimulation test (CST) is used to diagnose non-classic congenital adrenal hyperplasia (NCCAH). The current recommendation is to perform CST when follicular 17-hydroxyprogesterone (17OHP) is 6-30 nmol/L, a cutoff derived from radioimmunoassay (RIA). Recently, enzyme-lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakhleh, Afif, Saiegh, Leonard, Shehadeh, Naim, Weintrob, Naomi, Sheikh-Ahmad, Mohammad, Supino-Rosin, Lia, Alboim, Sandra, Gendelman, Raya, Zloczower, Moshe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871807/
https://www.ncbi.nlm.nih.gov/pubmed/36704043
http://dx.doi.org/10.3389/fendo.2022.1048663
_version_ 1784877263363244032
author Nakhleh, Afif
Saiegh, Leonard
Shehadeh, Naim
Weintrob, Naomi
Sheikh-Ahmad, Mohammad
Supino-Rosin, Lia
Alboim, Sandra
Gendelman, Raya
Zloczower, Moshe
author_facet Nakhleh, Afif
Saiegh, Leonard
Shehadeh, Naim
Weintrob, Naomi
Sheikh-Ahmad, Mohammad
Supino-Rosin, Lia
Alboim, Sandra
Gendelman, Raya
Zloczower, Moshe
author_sort Nakhleh, Afif
collection PubMed
description CONTEXT: The 250µg-cosyntropin stimulation test (CST) is used to diagnose non-classic congenital adrenal hyperplasia (NCCAH). The current recommendation is to perform CST when follicular 17-hydroxyprogesterone (17OHP) is 6-30 nmol/L, a cutoff derived from radioimmunoassay (RIA). Recently, enzyme-linked immunosorbent assay (ELISA) has replaced RIA. OBJECTIVES: We aimed to (1) determine the RIA and ELISA-based 17OHP cutoffs at which CST should be performed, (2) identify predictors of NCCAH. METHODS: A retrospective study at an Israeli Health Maintenance Organization. Data were retrieved from women with suspected NCCAH, referred for CST during 2001–2020. NCCAH was defined as a stimulated 17OHP >30 nmol/L. Serum 17OHP levels were assayed by RIA from 1/2000-3/2015, and by ELISA from 4/2015-12/2020. ROC curves were generated and optimal 17OHP thresholds were determined. Multivariate analysis was performed. RESULTS: CST was performed in 2409 women (1564 in RIA, 845 in ELISA). NCCAH was diagnosed in 4.7% of the RIA group and 7.5% of the ELISA group. The optimal basal 17OHP cutoff values predicting NCCAH were 6.1 nmol/L in RIA (sensitivity=93.2%, specificity=91.7%) and 8.2 nmol/L in ELISA (sensitivity=93.7%, specificity=92.3%). In multivariate analysis, higher basal 17OHP, lower LH: FSH ratio, and oligomenorrhea were predictors of NCCAH in RIA. Higher basal 17OHP, androstenedione, and total testosterone were predictors of NCCAH in ELISA. A lower LH: FSH ratio showed similar trend in ELISA. CONCLUSIONS: Optimal RIA-based basal 17OHP cutoff was comparable with that recommended in guidelines. The results suggest adopting a higher 17OHP cutoff when using ELISA. LH : FSH ratio improves the negative predictive value of basal 17OHP.
format Online
Article
Text
id pubmed-9871807
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98718072023-01-25 Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays Nakhleh, Afif Saiegh, Leonard Shehadeh, Naim Weintrob, Naomi Sheikh-Ahmad, Mohammad Supino-Rosin, Lia Alboim, Sandra Gendelman, Raya Zloczower, Moshe Front Endocrinol (Lausanne) Endocrinology CONTEXT: The 250µg-cosyntropin stimulation test (CST) is used to diagnose non-classic congenital adrenal hyperplasia (NCCAH). The current recommendation is to perform CST when follicular 17-hydroxyprogesterone (17OHP) is 6-30 nmol/L, a cutoff derived from radioimmunoassay (RIA). Recently, enzyme-linked immunosorbent assay (ELISA) has replaced RIA. OBJECTIVES: We aimed to (1) determine the RIA and ELISA-based 17OHP cutoffs at which CST should be performed, (2) identify predictors of NCCAH. METHODS: A retrospective study at an Israeli Health Maintenance Organization. Data were retrieved from women with suspected NCCAH, referred for CST during 2001–2020. NCCAH was defined as a stimulated 17OHP >30 nmol/L. Serum 17OHP levels were assayed by RIA from 1/2000-3/2015, and by ELISA from 4/2015-12/2020. ROC curves were generated and optimal 17OHP thresholds were determined. Multivariate analysis was performed. RESULTS: CST was performed in 2409 women (1564 in RIA, 845 in ELISA). NCCAH was diagnosed in 4.7% of the RIA group and 7.5% of the ELISA group. The optimal basal 17OHP cutoff values predicting NCCAH were 6.1 nmol/L in RIA (sensitivity=93.2%, specificity=91.7%) and 8.2 nmol/L in ELISA (sensitivity=93.7%, specificity=92.3%). In multivariate analysis, higher basal 17OHP, lower LH: FSH ratio, and oligomenorrhea were predictors of NCCAH in RIA. Higher basal 17OHP, androstenedione, and total testosterone were predictors of NCCAH in ELISA. A lower LH: FSH ratio showed similar trend in ELISA. CONCLUSIONS: Optimal RIA-based basal 17OHP cutoff was comparable with that recommended in guidelines. The results suggest adopting a higher 17OHP cutoff when using ELISA. LH : FSH ratio improves the negative predictive value of basal 17OHP. Frontiers Media S.A. 2023-01-10 /pmc/articles/PMC9871807/ /pubmed/36704043 http://dx.doi.org/10.3389/fendo.2022.1048663 Text en Copyright © 2023 Nakhleh, Saiegh, Shehadeh, Weintrob, Sheikh-Ahmad, Supino-Rosin, Alboim, Gendelman and Zloczower https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Nakhleh, Afif
Saiegh, Leonard
Shehadeh, Naim
Weintrob, Naomi
Sheikh-Ahmad, Mohammad
Supino-Rosin, Lia
Alboim, Sandra
Gendelman, Raya
Zloczower, Moshe
Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays
title Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays
title_full Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays
title_fullStr Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays
title_full_unstemmed Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays
title_short Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays
title_sort screening for non-classic congenital adrenal hyperplasia in women: new insights using different immunoassays
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871807/
https://www.ncbi.nlm.nih.gov/pubmed/36704043
http://dx.doi.org/10.3389/fendo.2022.1048663
work_keys_str_mv AT nakhlehafif screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays
AT saieghleonard screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays
AT shehadehnaim screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays
AT weintrobnaomi screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays
AT sheikhahmadmohammad screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays
AT supinorosinlia screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays
AT alboimsandra screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays
AT gendelmanraya screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays
AT zloczowermoshe screeningfornonclassiccongenitaladrenalhyperplasiainwomennewinsightsusingdifferentimmunoassays